Results 51 to 60 of about 24,190 (185)

The Therapeutic Potential of H2S‐Releasing Platforms in Cardiovascular Applications

Journal of Biomedical Materials Research Part B: Applied Biomaterials, Volume 114, Issue 8, August 2026.
The Therapeutic Potential of H2S‐Releasing Platforms. ABSTRACT Once known as a toxic gas, hydrogen sulfide (H2S) is now making its way into many therapeutic applications. Similar to its other fellow endogenous gasotransmitters, nitric oxide and carbon monoxide, H2S is a small gas with a short half‐life, making it extremely capable of penetrating ...
Tia N. Shorter, Elizabeth J. Brisbois
wiley   +1 more source

Prediction of Coronary Artery Restenosis in Patients Undergoing Angioplasty

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2018
BACKGROUND AND OBJECTIVE: Coronary artery restenosis following angioplasty may lead to major unwanted cardiac events. This is one of the most important concerns of cardiologists.
F Ebrahimzadeh, M Salehi Veisi, E Hajizadeh, M Namdari   +3 more
doaj  

Impact of Proton Pump Inhibitor Use on Outcomes Following Carotid Artery Stenting for Asymptomatic Carotid Stenosis: A Population‐Based Cohort Study

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 8, August 2026.
ABSTRACT Carotid artery stenting (CAS) is an effective treatment for carotid stenosis. Proton‐pump inhibitors (PPIs) are commonly prescribed in the general population. However, the impact of PPI use on outcomes following CAS remains unknown. This study investigated the impact of PPI use on CAS using a retrospective, matched‐cohort analysis from the ...
Chia‐En Wong, Pang‐Shuo Perng, Pei‐Wen Chen, Yu Chang, Chih‐Hao Tien, Jung‐Shun Lee, Liang‐Chao Wang, Chih‐Yuan Huang   +7 more
wiley   +1 more source

Restenosis risk factors after coronary stenting in metabolic syndrome patients

Кардиоваскулярная терапия и профилактика, 2007
This review is devoted to coronary restenosis after stent implantation in metabolic syndrome (MS) patients. It is known that some clinical factors increase restenosis risk, first of all, diabetes mellitus.
N. M. Danilov, T. T. Gorgadze, A. P. Savchenko, I. E. Chazova   +3 more
doaj  

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

VIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda, Tatsuya Watanabe, Satoshi Yuhara, John M. Kelly, Hirotsugu Kurobe, Toshiharu Shinoka   +5 more
wiley   +1 more source

Intractable coronary fibromuscular dysplasia leading to end‐stage heart failure and fatal heart transplantation

ESC Heart Failure, 2020
Coronary fibromuscular dysplasia is uncommon, and even rarer its unstable and recurrent course. We present the unique case of a 52‐year‐old woman who underwent in total 12 coronary angiographies and three percutaneous coronary intervention within 24 ...
Magdalena Maria Cattaneo, Marco Moccetti, Mattia Cattaneo, Daniel Sürder, Thomas Suter, Michele Martinelli, Eva Roost, Jürg Schmidli, Yara Banz, Carmen Schneiders, Giovanni Pedrazzini, Roberto Corti, Lorenz Räber, Filippo Crea, Paul Mohacsi, Augusto Gallino   +15 more
doaj   +1 more source

The Current State of MicroRNAs as Restenosis Biomarkers

Frontiers in Genetics, 2020
In-stent restenosis corresponds to the diameter reduction of coronary vessels following percutaneous coronary intervention (PCI), an invasive procedure in which a stent is deployed into the coronary arteries, producing profuse neointimal hyperplasia. The
Nelson Varela, Fernando Lanas, Fernando Lanas, Luis A. Salazar, Tomás Zambrano   +4 more
doaj   +1 more source

Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management

European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.
As transcatheter treatment expands to younger and lower‐risk patients, aortic stenosis management is evolving from a single procedure to lifelong valve care. This review highlights the key challenges across the patient journey, from timely diagnosis and optimal intervention to durable valve performance, long‐term surveillance, and repeat intervention ...
Ottavia Cozzi, Thomas Pilgrim
wiley   +1 more source

Restenosis after coronary angioplasty: An overview

Journal of the American College of Cardiology, 1991
Despite substantial basic and clinical efforts to address the problem of restenosis after percutaneous coronary intervention, effective preventive therapies have not yet been developed. Nevertheless, the accumulated information has provided much insight into the process of restenosis in addition to allowing standards to be developed for adequate ...
Califf, Robert M., Fortin, Donald F., Frid, David J., Harlan, William R., Ohman, E.Magnus, Bengtson, James R., Nelson, Charlotte L., Tcheng, James E., Mark, Daniel B., Stack, Richard S.   +9 more
openaire   +2 more sources

Biodegradable Zn‐Based Implants: Progress, Challenges, and Pathways toward Clinical Translation

Advanced Science, Volume 13, Issue 39, 13 July 2026.
Exploring biodegradable Zn‐based implants offers a promising pathway to next‐generation biomedical devices with balanced degradation and biocompatibility. A comprehensive overview of biodegradable Zn‐based implants, covering their biological significance, material design principles, and advanced engineering strategies is provided.
Panfeng Zhao, Zhengquan Wang, Hui Yang, Xiyuan Zhang, Hanyuan Liu, Xiaotong Lu, Xiaocheng Li, Yanyan Liu, Xi Zhao, Wenhao Zhou, Yufeng Zheng   +10 more
wiley   +1 more source